Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEN003694 and Entinostat in Advanced and Refractory Solid Tumors
NCT05053971Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ZEN3694 in solid tumor, pancreatic cancer (PC), sponsored by National Cancer Institute. Started Nov 2022; status: recruiting.
02
Drugs
ZEN3694
03
Conditions
solid tumorpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05053971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05053971.